Solutions, Ltd., a leading innovative, global biopharmaceutical company
in Guangzhou, China, is dedicated to researching and developing novel
therapeutics for the treatment of cancer, autoimmune, cardiovascular and eye diseases,
and other severe unmet medical needs, as well as biosimilars for
existing, branded biologics to treat a range of cancer and autoimmune diseases.
As a leader in next generation antibody discovery and engineering, the company
has advanced multiple candidates into late-stage development, including three approved products, QLETLI®, POBEVCY® and BAT1806 in China and Tocilizumab(BAT1806/TOFIDENCE) in US. In addition, the company has over 20 promising candidates in
clinical trials, focusing on immuno-oncology in the post-PD-1 era and targeted therapies such as antibody drug conjugates (ADC).